CANNAINVESTOR Magazine U.S. Publicly Traded April 2018 | Page 72
NanoSphere researches, develops and commercializes a
diverse line of product formulations based on the NanoSphere
Delivery System™ to meet the needs of healthcare providers,
consumers and suppliers. The NanoSphere Delivery System™
is the first to apply nanotechnology to improve the
bioavailability and efficacy of essential ingredients and
medications. This
disruptive technology
introduces a significant
advancement in these
industries. NHS is the
only nanotechnology
company who plans
to offer vertically integrated,
commercial lines.
Left: Evolve Formulas’ game-changing transdermal
product NanoSerum™, enables cannabis to be rapidly
absorbed into systemic circulation for direct-focus relief from
pain, inflammation and anxiety.
Strategic Direction Technology & Innovation
NanoSphere’s initial product deployment is NanoSphere has developed a revolutionary,
for the cannabinoid market, targeting both multiple patent-pending method for the
the medical marijuana market and, where non-invasive delivery of bioactive compounds,
legalized, the recreational usage market. such as cannabinoids, nutraceuticals,
NanoSphere has already partnered with a pharmaceuticals and over-the-counter medications, into
licensee in Colorado, and in late spring the body with greater efficiency than many traditional delivery systems. The
2017 launched its first award-winning NanoSphere Delivery System™ encapsulates these compounds in protective
cannabinoid product line, branded Evolve nano-sized spheres for transport directly into the bloodstream and cells. Our
NanoSerum, in the Colorado market. ongoing research and successful pharmacokinetic blood studies of our
NanoSphere will further license its technology have confirmed the greater bioavailability, bioactivity and efficacy of
intellectual property and proprietary our delivery system.
manufacturing method to selected cannabis
cultivators, extractors and distributors on a
state-by-state basis and abroad, and is
currently in discussions with operators in
several states to replicate the business
model in Colorado. Other planned future
deployments include nutraceuticals,
nonsteroidal anti-inflammatory drugs and
animal health applications.
Intellectual Property Overview
Our patent-pending portfolio includes: U.S. patent-pending 61/890,773:
Nutraceutical Delivery Utilizing Nano Particle Compositions, 62/091,994:
Nanoparticle Encapsulation To Treat And Prevent Global Inflammation And Pain,
62/130,775: Lipid Nanoparticle Compositions and Methods as Carriers of
Cannabinoids.
CSE: NSHS